NEW YORK (GenomeWeb) – Curetis reported today that its first quarter revenues rose 161 percent on continued demand for its Unyvero molecular diagnostic system.

For the three-month period ended March 31, Curetis' revenues increased to €347,166 ($388,393) from €132,810 a year earlier.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.